Brief: Isofol Receives Approval Of Biomarker Analysis Patent

Isofol Medical AB (publ)

26/07/2022 12:54

July 26 (Reuters) - Isofol Medical AB (publ)  ISOFOL.ST :
    * RECEIVES APPROVAL OF BIOMARKER ANALYSIS PATENT AND
INTENTION-TO-GRANT PATENT APPLICATION FOR STUDY DOSE REGIMEN IN
EUROPE
    * PATENT APPROVED COVERING CLINICAL USE OF A BIOMARKER
ANALYSIS IS
VALID UNTIL 2035 AND WAS APPROVED IN US IN 2019
    * DOSE REGIMEN PATENT COVERING CLAIM OF USE OF ARFOLITIXORIN
FOR
TREATMENT OF COLORECTAL CANCER PATIENTS IS VALID UNTIL 2039

Source text for Eikon:  ID:nWkr7SSBBg 
Further company coverage:  ISOFOL.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))